The life-science incubator in Geneva

The life-science incubator in Geneva

The life-science incubator in Geneva

23

Companies supported in 2018

54

Collaborators in the Eclosion environment in 2018

130

Millions CHF of capital raised in 2018

Molecular

Mission

The Foundation Eclosion mission is to foster entrepreneurs in translating their life science innovation into economic value and jobs in the Geneva’s region.

Offer

We provide entrepreneurs with the key resources required to bridge the gap from laboratory to start-up:

  • LABORATORY AND OFFICE INFRASTRUCTURE
  • BUSINESS AND SCIENTIFIC SUPPORT
  • FINANCIAL SUPPORT
  • OTHER SERVICES

Offer

We provide entrepreneurs and scientists with the key ressources to cross the bridge frpom laboratory to the start-up:

  • Infrastructure
  • Business and scientific support
  • Funding
  • Other services
Infrastructure

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilising more than 400 sq m of fully equipped laboratories and 300 sq m of office space located at the CTN (Centre des Technologies Nouvelles).

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilizing more than 300 sq m of laboratories located at the CTN (Centre des Technologies Nouvelles) and 500 sq m of offices

Infrastructure

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science and finance professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Financial Support

Eclosion services include financial support to conduct key experiments and access to the finance community to seed and fund start-up companies.

Financial Support

Eclosion services include financial support to conduct key experiments and access to the finance community to seed and fund start-up companies.

Other services

Eclosion also provides a wide range of additional services including administration, accounting and payroll support.

Other Services

Other services

Eclosion also provides a wide range of additional services, including administration, accounting and payroll support, as well as access to business intelligence databases.

Other Services

Community

Eclosion is fully integrated in the vibrant life-science community of Geneva and Switzerland, including economic promotion agencies, investors and research institutes.

Leadership

The team

Christophe Guichard

Christophe is dedicating his energy and passion to life-science start-up companies as Director of Eclosion since 2008. He is also contributing his experience in managing finance and legal activities and served as CFO for companies including GeNeuro, GenKyoTex and DepGen, raising over CHF 150m in equity. Prior to joining Eclosion, he held various corporate finance positions including CFO of a European listed company and manager with KPMG-Salustro, building organizations and performing M&A transactions and two IPOs. Christophe is a graduate from EDHEC Business School and from Harvard Business School. He also holds a postgraduate degree in Finance and Accounting (DESCF).

Yann Dean

Yann Dean holds a PhD from the University Of Wales College Of Medicine, Cardiff, UK. He has 15 years of experience in the biotech sector. Before joining Eclosion, Yann worked at NovImmune SA, where he developed one therapeutic monoclonal antibody from research to clinical phase IIa as Project Leader and participated in the development (from bench to bedside) of five other monoclonal antibodies as Preclinical Manager. Yann has published several peer-reviewed scientific articles and authored multiple patents related to the validation of therapeutic targets and development of biological drugs.

Farid Bouzidi

Farid joined Eclosion as Scientific Director. Farid has more than 15 years’ experience in Business/Corporate/Product Development across a range of clinical indications including CNS, autoimmune diseases, oncology, and infectious diseases. With his experience at Institut Pasteur, he has a strong emphasis on entrepreneurship, value creation and incubation. He has worked in many organisations including Genentech, Roche, AC Immune and as an independent consultant covering projects from discovery to clinical development and marketed products. Farid is currently a senior advisor to the Institut Pasteur for innovative projects. Farid obtained his Ph.D. in Biophysics and Biochemistry from CEA and MBA from EM-Lyon, France.

Operational and Scientific Management

Yann Dean holds a PhD from the University Of Wales College Of Medicine, Cardiff, UK. He has 15 years of experience in the biotech sector. Before joining Eclosion, Yann worked at NovImmune SA, where he developed one therapeutic monoclonal antibody from research to clinical phase IIa as Project Leader and participated in the development (from bench to bedside) of five other monoclonal antibodies as Preclinical Manager. Yann has published several peer-reviewed scientific articles and authored multiple patents related to the validation of therapeutic targets and development of biological drugs.

Marlène Bon holds a Higher Diploma in Accounting and Management.        Having practiced as an Accountant, she joined a local SME (Small and Medium Enterprise) and took part in its development in the role of Administrator (Accounting and Human Relations). She became Office Manager of Eclosion      in June, 2014.

Foundation Council

Monica Malcarne is currently the Site Lead for Covance Central Laboratory and Director of Sample & Archive Services, servicing all clinical trials for Central and Early Development laboratories based in the US and in Europe. Her responsibilities included Laboratory Pre/Post-Analytical Sample Management, BioRepository Services and Archive Services. She joined SciCor (now Covance) in 1995 as Investigator Services Administrator before moving to a Project Manager role, executing Study Design, Coordination and Management for key accounts.  In 2002 she moved into leadership roles starting with Team Manager in Geneva and Indianapolis where she relocated in 2004. In 2006 she ensured the General Management of our operations in Shanghai, China and then in Zeist, the Netherlands were she transferred until end of 2007. Relocating in Geneva in 2008 she accepted the role of Director of Global Laboratory Support Services before taking the role of Director of Global Sample Services. As the Site Lead of the Geneva site, Monica enabled opportunities and initiatives in a sustainable way while cultivating an inclusive approach, such as events for the employees by the employees in the sport, health and wellness areas, corporate social responsibility and communication. Monica holds a Master of Art degree in Social and Political Sciences from Lausanne University, Switzerland.

Christine Deuschel is Senior Consultant, Life Sciences, Thalent SA. She brings more than 20 years of experience in the pharma an industry and diagnostics. Prior to Thalent She served as Senior VP, Portfolio and Project management office at Debiopharm International SA responsible for the portfolio of drug discovery and development. She held positions of increasing responsibilities in startup, biotech & medtech and served as board member and chair of diagnostic companies. She also managed commercial exploitation of academic research at University of Geneva. She is a Venturelab Trainer for the Innosuisse Start-up Training, Biotech. Christine holds a PhD in chemistry, and MBA of EPFL/HEC Lausanne

Antoine Geissbuhler is a Professor of Medicine, Chairman of the Department of Radiology and Medical Informatics at Geneva University, Director of the Division of eHealth and Telemedicine at Geneva University Hospitals. He is also President of the Health-On-the-Net Foundation, Past-President of the International Medical Informatics Association, and Fellow of the American College of Medical Informaticians. His research focuses on the development of innovative, knowledge-enabled information systems and computer-based tools for improving the quality, safety and efficiency of care processes, and on the evaluation of their impact on health outcomes, at the local level of the largest hospital in Switzerland, in the regional patient-centered health information system, at the global level with the Health-On-the-Net Foundation, as director of the WHO collaborating center for eHealth, and as director of the RAFT network, an extensive South-South telemedicine network linking hundreds of hospitals in 20+ developing countries (http://raft.network).

With a degree in economics from Fribourg University, Daniel Loeffler is the Deputy Secretary-general to the Department of Economic Develpment of the Canton of Geneva. Prior to his current position, he managed Geneva’s Economic Development Office during 8 years. In his capacity as Director, Daniel was in charge of implementing the cantonal economic development strategy, built around the support of innovation, the development of clusters and international markets. Previously, he had been a business consultant in financing and project management. Daniel worked also in the fields of fund raising and controlling systems implementation in SME’s at the CCSO in Geneva.

Robin Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Robin serves as a board member and is Chairman of the Advisory Board of Eclosion

Prior to co-founding Medicxi, Michèle Ollier was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time, she invested and continues to serve on boards of a number of Index Life Sciences portfolio companies including Palladio Biosciences, Gadeta BV, Epsilon 3 Bio Ltd. She also sits on the boards of Human Antibody Factory Ltd, Linguaflex and Diasome, one of the first investments of the Medicxi Growth Fund. She was also a Director at OncoEthix (sold to Merck Pharmaceuticals), Minerva Neurosciences (Nasdaq: Nerv) and Aegerion (Nasdaq: Aegr). Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Gencell/Aventis International and Serono International.  She currently serves on the board of directors of Ipsen Pharmaceuticals

(Euronext: IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord. Michèle completed her medical studies in France at Paris Ouest University.

Julien Storaï has done all his carrier in Biotech and Pharma Manufacturing. He holds an MSc of Biochemistry Engineer combined with an MSc of Industrial Microbiology. Between 2004 and 2007 he gained a PhD in Industrial Microbiology following a collaboration between CNRS and Sanofi-Pasteur. He joined OM Pharma in 2008 (fully integrated within Vifor Pharma since 2009) as Head of Fermentation Unit and progressively took growing responsibilities in Industrial Operations. Since 2016, Julien is the Site Manager of Geneva Site leading around 200 people.

Beyond a solid Biotech Background, Julien is also Black Belt Certified and was in charge to deploy Operational Excellence on Geneva Site and beyond within Vifor Pharma over the last years.

Advisory board

Professor Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Mr. Offord serves as a board member and is Chairman of the Advisory Board of Eclosion.

Oliver Hartley is an associate professor at the Faculty of medicine, University of Geneva.  In 1997 he completed a PhD in protein engineering with Sir Gregory Winter, a Nobel laureate (2018) and serial entrepreneur. Subsequently, Oliver has worked at the University of Geneva, mainly focusing on discovering and optimizing chemokine analogs as new medicines. This work has led to a series of high-profile publications and new intellectual property. In 2005 he co-founded the Mintaka Foundation for Medical Research (www.mintakafoundation.org) as Chief Scientific Officer, in order to translate his anti-HIV chemokine analog work from the lab to the clinic. Mintaka successfully raised approximately $10 million in non-profit funding and used these resources to successfully complete preclinical work for the lead molecule, 5P12-RANTES, which has now been acquired for further development by Orion Biotechnology (www.orionbiotechnology.com, for whom Oliver has worked since 2019 as VP for Drug Discovery), and will enter a first clinical study in 2019.

Denis Hochstrasser is a practising internist and clinical chemist. He manages the clinical pathology department and the central clinical chemistry and biological examination laboratories at Geneva’s university hospitals, supervises the computational activities of the medicine faculty at Geneva University, and runs a leading international multidisciplinary research group in proteomics. Prof. Hochstrasser cofounded the Institut Suisse de Bioinformatique, GeneBio SA, and Geneprot Inc.

Karl-Heinz Krause is Professor of Medicine at the Faculty of Medicine & University Hospitals of Geneva, as well as honorary professor at the Bejing Hospital, China. He received his MD from the Ludwig-Maximilian University (Munich) in 1982. From 1982 to 1989, he received clinical training in internal medicine and infectious diseases at the Universities of Munich, Geneva and Iowa. Starting in 1984, Prof. Krause has been actively involved in inflammation research. Since 1998, he has focused his research further on mechanisms of aging and treatment of age-associated diseases, in particular on the NOX family of NADPH oxidases as a pathophysiologically important source of oxygen radicals. He is an elected member of the Swiss Academy of Medical Sciences and the American Society for Clinical Investigation

Jean-Yves Le Cotonnec obtained a bachelor’s degree in engineering, a doctorate in medicine and a master’s in statistics in Paris. For 14 years, he occupied senior positions in the pharmaceutical industry, including posts at Novartis and Serono. In 1995 he founded Triskel Integrated Services SA, a company that defines and implements strategies to develop and register medical products in Europe and the USA, working in strategic cooperation with traditional contract research and manufacturing organisations. He has been involved in the development and registration of over ten drugs, including several blockbusters.

Frédéric Levy  and his team manage the Evaluation of innovative therapeutics at Debiopharm International SA in Lausanne, Switzerland. He obtained his doctoral degree in biochemistry at the Karolinska Institute in Stockholm, Sweden and spent several years as a postdoctoral fellow at the California Institute of Technology in Pasadena. He moved then to Switzerland to take a position at the Lausanne Branch of the Ludwig Institute for Cancer Research, where he successively awarded a Young Investigator Award of the Cancer Insitute, a Professorship of the Swiss National Funds, an Associate Membership of the Ludwig Institute and an Associate Professorship of the University of Lausanne. His area of expertise is drug development in oncology, immunology and infectious diseases. During his career, Frédéric was Vice President of the Swiss Society of Biochemistry, Board Member of the Platform Biology of the Swiss Academy of Science, jury member of the Friedrich Miescher Award and Board Member of the FEBS.

Andrew Parker has a Ph.D. from the National Institute for Medical Research (UK), carried out post-doctoral studies at Johns Hopkins School of Medicine (USA) and completed an MBA with Warwick Business School (UK). He has published more than 25 peer-reviewed scientific papers in renowned international journals. Andrew  has twenty years of experience in drug discovery and early clinical development within pharmaceutical and biotechnology sectors.  Actually, he is CSO at Zealand Pharma

Dr Sausen is the Vice President and Head of Early Phase Development Solutions (EPDS) and has served in this capacity since July 2015. In his current role, he has responsability for leading the scientific and strategic direction of EPDS, a multi-disciplined approach to drug development designed to enhance coordination from Late Lead Optimization through proof of concept, therevy reducing the time and cost of molecule development. Dr Sausen joined Covance in 2005 as Executive Director in the Program Management Group. During his tenure with Covance, he has served in multiple Executive Management positions in Program Management Integrated Drug Development, Nonclinical Safety Assessment, Safety Assessment and Global Safety Assessment. Dr Sausen is diplomat of the American Board of Toxicology, a member of the Society of Toxicology, Phi Beta Kappa and Beta Beta Beta (National Biology Honor Society). He has authored/co-auhored more than a dozen publications and has presented at more than a dozen conferences. Dr Sausen has a bachelor degree in Biology and Chemistry from Ripon College in Wisconsin and earned his PhD in Toxicology from the University of Wisconsin-Madison.

Oern R. Stuge is director of Impulse Dynamics NV. He was first Vice President, a member of the operating committee member and president for Europe, Canada, Latin America and emerging markets at Medtronic Inc. His numerous life sciences projects in areas such as Rx, Dx, nutrition and medical devices have given significant experience and a reputation as a leading force in this domain. Oern was a member of Medtronic’s management team for 12 years, serving as president for cardiac surgery and president for Europe and Central Asia, where he was responsible for transforming the cardiac surgery business and accelerating the growth of Medtronic companies in Europe with cardiovascular, neurological and spinal franchises. Before joining Medtronic, Oern served first as CEO of Medinor A/S, a Norwegian medical technology company, and then for Abbott Laboratories, where he was regional director and managing director for the Netherlands and the Nordic countries. He is a principal adviser to HealthCap, a life sciences investment fund with $1.5 billion under management; a member of the supervisory board of Mediq BV, an international medicines and pharmaceuticals distributor; and a director of Nobel Biocare AG, a world leader in dental implants. Dr Stuge graduated in medicine at Oslo University, and gained an MBA from the IMD business school in Lausanne

Timothy Wells is the Chief Scientific Officer for MMV, Medicines for Malaria Venture. Before joining that organisation, he was senior executive Vice President of research for Serono, conducting clinical trials on a number of innovative molecules. From 1997 to 2007, he worked at Glaxo’s molecular biology institute in Geneva, where he managed research into protein biochemistry and chemotactic cytokines. An enzymologist by training, his research interests included the relationships between protein structure and function, and the role of cytokines in controlling host responses. He has contributed to over 180 scientific publications and several patent registrations. He gained a doctorate in chemistry from London’s Imperial College for his research into protein engineering under the supervision of Sir Alan Fersht, and then obtained an ScD from Cambridge University for his work on the cytokine biology. He is a member of the Royal Society of Chemistry.

Get in touch

Subscribe to Eclosion Newsletter

 

CONTACT US
© 2019 Fondation Eclosion
All rights reserved
Webdesign: Comstone / Pierre Chassany
WordPress Development: Vocables